How to apply for this EIS
- Click on the Download button below to obtain all relevant literature.
- Read all the literature provided in full, ensuring you’re happy to proceed.
- Post the completed forms along with two valid forms of ID, and a cheque made payable to the provider, to: WealthMe, PO Box 362, Burgess Hill, West Sussex, RH15 5BH.
Free EIS Guide
Download our free & comprehensive guide to EIS. All investment decisions must be made solely on the fund's prospectus.
Fund title: The o2h therapeutics AI SEIS and EIS Fund
the o2h therapeutics and AI S/EIS Fund
o2h Ventures Limited, an investment firm based in Cambridge, UK, manages “the o2h therapeutics and AI S/EIS fund” which is Britain's first ever EIS and/or SEIS investment fund backing early stage biotech therapeutic and related AI opportunities.
The investment focus of the fund will be therapeutic drug opportunities or technologies that enable drug discovery with an emphasis on Artificial Intelligence (AI). The geographic scope shall be UK wide including Oxford and London but will target the growing Cambridge biotech cluster which is now the global headquarters of AstraZeneca, and is home to many biotech companies some of which have subsequently been snapped up by large pharmaceutical companies.
Large pharmaceutical companies have been closing down research centres globally for the last decade. This shift in focus of the large pharmaceutical companies has moved them from developing innovation in-house to acquiring innovation externally, forcing up the prices for the best science and providing earlier exit opportunities.
The team at o2h have access to the most exciting scientific ideas through its live working relationships fostered over many years working as a discovery services company. This gives us far earlier access than competitors to the most promising companies.
6 investments have been made so far from the fund in some of the most promising early stage biotech companies in the UK since the launch – with few more investments lined up to be made before end of the year.
Sunil Shah co-founded o2h Ventures Ltd with his brother Prashant Shah in the year 2018. o2h operate from their proprietary 2.7 acre The Mill SciTech Park where they are developing a unique model for incubating small life science companies.
The fund is structured to be S/EIS compliant providing generous income, Inheritance and capital gains tax breaks for UK tax payers.
*Rebate - Total 1% - ie Initial commission rebate 2%. The WealthMe 1% Arrangement fee is paid by the product provider from the Initial Charge.
If applicable we will ask the product provider to reinvest any initial or trail commission back into your plan. This will be either in the form of a reduction in their charges or an enhancement of additional shares. However if this cannot be facilitated, they will pay any initial or trail commission to WealthMe. We will then pay any surplus initial commission immediately back to the recipient. Any trail commission we receive will be paid to the recipient in January based on the amount received in the previous year (subject to a £10 administration fee). All initial and trail rebates will be paid net of basic rate tax and are to be treated as taxable income by the recipient as stipulated by HMRC.
WealthMe Arrangement Fee
Expected Close date
Funds Raised and sought
£1.5m of £10m
The information given here has been taken from the product terms and conditions, brochure, and other literature available from the product provider. However, no guarantee can be made to the accuracy of the information. You should therefore satisfy yourself as to the full terms and risks of any investment by reference to the relevant materials provided by the product provider. In the unlikely event of any discrepancy between the information shown here and that provided in the provider literature, the product literature shall prevail. All investment involves risk and you could lose some or all of the money you invest.